Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec.

Conclusion: These insights may further inform the development of policies or procedures to incorporate talimogene laherparepvec into clinical settings and improve patient outcomes.
PMID: 30210146 [PubMed]

Source: Herpes - September 15, 2018 Category: Infectious Diseases Authors: McBride A, Valgus J, Parsad S, Sommermann EM, Nunan R Tags: Hosp Pharm Source Type: research